On Tuesday, Cartesian Therapeutics Inc (NASDAQ: RNAC) opened higher 17.56% from the last session, before settling in for the closing price of $6.72. Price fluctuations for RNAC have ranged from $5.98 to $26.20 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 34.24% over the past five years. Company’s average yearly earnings per share was noted 49.13% at the time writing. With a float of $9.46 million, this company’s outstanding shares have now reached $26.00 million.
Cartesian Therapeutics Inc (RNAC) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cartesian Therapeutics Inc is 63.62%, while institutional ownership is 19.49%. The most recent insider transaction that took place on Dec 04 ’25, was worth 205,797. In this transaction Director of this company bought 30,000 shares at a rate of $6.86, taking the stock ownership to the 54,366 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Former Affiliate proposed sale 26,935 for $7.15, making the entire transaction worth $192,585.
Cartesian Therapeutics Inc (RNAC) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.59 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.83) by 0.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.86 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.57% during the next five years compared to 34.24% growth over the previous five years of trading.
Cartesian Therapeutics Inc (NASDAQ: RNAC) Trading Performance Indicators
Check out the current performance indicators for Cartesian Therapeutics Inc (RNAC). In the past quarter, the stock posted a quick ratio of 13.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -52.64, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -3.33 in one year’s time.
Technical Analysis of Cartesian Therapeutics Inc (RNAC)
Cartesian Therapeutics Inc (NASDAQ: RNAC) saw its 5-day average volume 0.34 million, a positive change from its year-to-date volume of 94457.0. As of the previous 9 days, the stock’s Stochastic %D was 39.42%.
During the past 100 days, Cartesian Therapeutics Inc’s (RNAC) raw stochastic average was set at 22.38%, which indicates a significant decrease from 73.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.51 in the past 14 days, which was lower than the 0.65 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.33, while its 200-day Moving Average is $11.00. Nevertheless, the first resistance level for the watch stands at $8.50 in the near term. At $9.09, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.79. If the price goes on to break the first support level at $7.21, it is likely to go to the next support level at $6.51. Assuming the price breaks the second support level, the third support level stands at $5.92.
Cartesian Therapeutics Inc (NASDAQ: RNAC) Key Stats
There are currently 26,004K shares outstanding in the company with a market cap of 205.42 million. Presently, the company’s annual sales total 38,910 K according to its annual income of -77,420 K. Last quarter, the company’s sales amounted to 450 K and its income totaled -35,900 K.
